Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company's operating segments include Proprietary Development and Partnered Discovery. In the Proprietary Development segment, it develops therapeutic antibodies and peptides in the area of inflammatory disease and oncology. In the Partnered Discovery segment, the Company applies technologies for the research, development and optimization of therapeutic antibodies as drug candidates. The Company develops new treatments for patients suffering from serious diseases. Its technologies include HuCAL, which is a collection fully human antibodies and a system for their optimization; Ylanthia, which is an antibody library in Fab format, and Slonomics, an automated technology for gene synthesis and modification for the generation of gene libraries in a controlled process.

  • Revenue in EUR (TTM)195.10m
  • Net income in EUR-851.39m
  • Incorporated1998
  • Employees648.00
  • Location
    MorphoSys AGSemmelweisstr. 7PLANEGG 82152GermanyDEU
  • Phone+49 89899270
  • Fax+49 8 989927222
  • Websitehttps://www.morphosys.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
BRAIN Biotech AG44.48m-7.64m155.12m303.00--5.12--3.49-0.3653-0.36532.121.390.5982.346.05139,880.50-9.93-12.40-13.38-15.8258.2656.09-16.61-24.531.94-5.140.4309--0.40459.3948.66--0.5024--
Heidelberg Pharma AG12.87m-21.65m178.40m93.00------13.87-0.6339-0.63390.3768-0.04610.51857.5813.39144,563.60-87.26-57.79-730.90-76.7551.1925.52-168.30-334.400.728-26.261.11---79.385.14-42.30--20.89--
Northern Data AG16.38m-84.26m535.85m157.00--1.87--32.72-7.25-7.251.4112.06------104,314.40---35.75---72.5737.20-6.61-514.48-343.850.301-0.52520.2519--61.18577.19-861.89------
MorphoSys AG195.10m-851.39m767.82m648.00------3.94-24.93-24.935.71-0.8040.09552.221.79266,525.00-41.67-13.97-47.78-15.7378.40---436.39-89.382.91-4.031.09---45.1929.28-625.55--55.11--
Eckert&Ziegler Strahlen und Mdzntchnk AG186.17m27.33m926.06m930.0033.274.6524.964.971.311.318.959.410.55612.435.25214,974.608.228.389.8210.1350.1847.8414.7912.772.39--0.117735.572.445.5262.2027.0840.1724.82
Formycon AG41.69m-13.48m1.25bn171.00--16.34--30.10-1.22-1.223.795.100.587423.275.69243,783.60-18.99-6.59-21.58-7.3913.7429.53-32.33-8.863.68-56.680.00--20.3516.22-127.42---2.05--
Biotest AG511.50m-54.20m1.49bn1.97k--4.47--2.92-1.34-1.3413.139.480.45581.533.54260,040.70-4.82-2.44-5.39-2.8316.4027.69-10.58-5.862.33-3.050.5874--6.484.79-97.02---32.84--
Dermapharm Holding SE962.34m210.64m3.06bn2.37k14.535.7411.493.183.923.9217.889.920.70291.3611.86405,537.7015.3212.3717.3814.4665.8757.2121.8015.121.3995.580.5207--18.7816.23144.2065.6128.08--
Data as of Aug 05 2022. Currency figures normalised to MorphoSys AG's reporting currency: Euro EUR
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.